European Journal of Obstetrics & Gynecology and Reproductive Biology 2011-08-01

Atosiban versus betamimetics in the treatment of preterm labour in Italy: clinical and economic importance of side-effects.

Jaro Wex, Ahmed M Abou-Setta, Graziano Clerici, Gian Carlo Di Renzo

Index: Eur. J. Obstet. Gynecol. Reprod. Biol. 157(2) , 128-35, (2011)

Full Text: HTML

Abstract

The aim of this study was to determine the cost effectiveness of atosiban compared to betamimetics in the treatment of preterm labour within the Italian setting. A systematic literature review identified randomised controlled trials (RCTs) comparing atosiban with betamimetics. Meta-analysis of nine RCTs determined that atosiban and betamimetics had similar efficacy in delaying preterm birth by at least 48 h (p=0.910). Use of atosiban was associated with significantly fewer adverse events (p<0.008). Results demonstrate that atosiban is cost-saving versus ritodrine or isoxuprine. Atosiban cost savings are €657 per patient from the National Health Service payer's perspective; €299 at 18 h of tocolysis to €189 at 48 h from the hospital's perspective. The respective values versus isoxuprine were €303 and €199. From the combined perspective, using atosiban versus ritodrine saved from €425 to €316; and versus isoxuprine from €429 to €326. Owing to its superior safety profile, atosiban is cost-saving versus betamimetics in the treatment of preterm labour in Italy from the payer's, hospital's and combined perspectives. With the approximate 40,000 annual preterm births in Italy the annual savings could be in excess of €13 million for the payer or €3.8-6.2 million for the hospitals.Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.